A competing risk nomogram predicting cause-specific mortality in patients with lung adenosquamous carcinoma
Open Access
- 16 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 20 (1), 1-11
- https://doi.org/10.1186/s12885-020-06927-w
Abstract
Adenosquamous carcinoma (ASC) is an uncommon histological subtype of lung cancer. The purpose of this study was to assess the cumulative incidences of lung cancer-specific mortality (LC-SM) and other cause-specific mortality (OCSM) in lung ASC patients, and construct a corresponding competing risk nomogram for LC-SM. Data on 2705 patients with first primary lung ASC histologically diagnosed between 2004 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence function (CIF) was utilized to calculate the 3-year and 5-year probabilities of LC-SM and OCSM, and a competing risk model was built. Based on the model, we developed a competing risk nomogram to predict the 3-year and 5-year cumulative probabilities of LC-SM and the corresponding concordance indexes (C-indexes) and calibration curves were derived to assess the model performance. To evaluate the clinical usefulness of the nomogram, decision curve analysis (DCA) was conducted. Furthermore, patients were categorized into three groups according to the tertile values of the nomogram-based scores, and their survival differences were assessed using CIF curves. The 3-year and 5-year cumulative mortalities were 49.6 and 55.8% for LC-SM and 8.2 and 11.8% for OCSM, respectively. In multivariate analysis, increasing age, male sex, no surgery, and advanced T, N and M stages were related to a significantly higher likelihood of LC-SM. The nomogram showed good calibration, and the 3-year and 5-year C-indexes for predicting the probabilities of LC-SM in the validation cohort were both 0.79, which were almost equal to those of the ten-fold cross validation. DCA demonstrated that using the nomogram gained more benefit when the threshold probabilities were set within the ranges of 0.24â0.89 and 0.25â0.91 for 3-year and 5-year LCSM, respectively. In both the training and validation cohorts, the high-risk group had the highest probabilities of LC-SM, followed by the medium-risk and low-risk groups (both P < 0.0001). The competing risk nomogram displayed excellent discrimination and calibration for predicting LC-SM. With the aid of this individualized predictive tool, clinicians can more expediently devise appropriate treatment protocols and follow-up schedules.Keywords
Other Versions
Funding Information
- the national key Research and Development Program of China (2017YFC0113500)
- Zhejiang Province Major Science and Technology Special Project (2014C03032)
- Zhejiang Provincial Key Discipline of Traditional Chinese Medicine (2017-XK-A33)
This publication has 26 references indexed in Scilit:
- Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancerProstate Cancer and Prostatic Diseases, 2018
- Clinical characteristics and prognosis of patients with lung adenosquamous carcinoma after surgical resection: results from two institutesJournal of Thoracic Disease, 2018
- Cause-specific mortality in patients with head and neck cancer: Long-term follow-up of a population-based cohort from 1986 to 2012 accounting for competing risksOral Oncology, 2018
- Prediction of Competing Mortality for Decision-making Between Surgery or Observation in Elderly Patients With T1 Kidney CancerUrology, 2016
- Adenosquamous Carcinoma of the Lung: Surgical Management, Pathologic Characteristics, and Prognostic ImplicationsThe Annals of Thoracic Surgery, 2013
- A clinicopathological and immunohistological reâevaluation of adenosquamous carcinoma of the lungPathology International, 2011
- Adenosquamous carcinoma of the lung: surgical results as compared with squamous cell and adenocarcinoma casesEuropean Journal of Cardio-Thoracic Surgery, 2011
- Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After LobectomyThe Annals of Thoracic Surgery, 2010
- Prognostic impact of increasing age and co-morbidity in cancer patients: A population-based approachCritical Reviews in Oncology/Hematology, 2005
- Clinicopathologic characteristics of adenosquamous carcinoma of the lungCancer, 1991